Thursday, July 11, 2019

Update - July 11th, 2019

Webinars -

Dr. Ready on Promising Treatment Approaches in SCLC
OncLive
- Dr. Ready talks about the failure of Rova-T and how it still demonstrates the feasibility of DLL3 as a target antigen for future therapeutics

Regulatory -

Bluebird Bio delays Zynteglo launch as manufacturing trips up another gene therapy
FiercePharma
- The FDA is tightening the screws on their GMP Biologics expectations.  This isn't directly related to ADCs but make no mistake, this is a precendent that we all must follow

Manuscripts -

Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Journal of the National Cancer Institute
- A nice and recent update on the state of ADCs

Clinical Results -

MEN1309/OBT076, a first-in-class Antibody-drug Conjugate (ADC) targeting CD205 in solid tumors.
AACR - Molecular Cancer Therapeutics
- Oxford Bio is showing some good preclinical results about CD205 in TNBC grafts

Industry-

Seducing Pfizer: How Array’s team patiently worked up the ladder to win an $11.4B bid from Albert Bourla
Endpoints News
- Maybe its just me, but seeing behind the curtain about how these big M&A deals goes down is fascinating

BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Yahoo News
- BioAtla is bringing in some SeaGen muscle to help with their clinical trial platform

WUXI BIOLOGICS TO EXPAND INTEGRATED BIOLOGICS CONJUGATION SOLUTION CENTER TO INCLUDE COMMERCIAL MANUFACTURING
WuXi Press Release
- And WuXi continues on its path to world domination with a $10M expansion of their integrated biologics facility to include commercial product production

SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma
Yahoo Finance
- SpringWorks Therapeutics is entering into a clinical colab with GSK for their Belantamab Mafodotin ADC.  GSK has not gone commercial with their ADC yet, but with that fast approaching, expect more of these coming in the future

Who's the next Big Pharma takeout target? Biogen, uniQure, AZ top the list: report
FiercePharma
- With all of the M&A activity, asking the industry insiders who's next isn't a bad plan.  And AZ pops out pretty high on the list.  Could this be the next step in their line of major shakeups

-----------------------------
Thats it for today. There are always more coming down the pike. Is there something I missed? Contact me. Justin@ADCDaily.com
- - - [Main]

No comments:

Post a Comment